Organon intends to use Medarex’s UltiMAb human antibody development system, which allows for the discovery of fully human antibodies in mice, to generate therapeutic antibodies against a variety of disease targets.
Under the terms of the agreement Medarex will receive license fees and milestone payments as well as royalties on commercial sales of any products that may result from this agreement. Specific financial terms were not disclosed.
“We believe that Medarex’s UltiMAb system is a valuable addition to the proprietary technology of Organon for the generation of therapeutic monoclonal antibodies. These technologies complement each other and are instrumental in supporting the Organon strategy to build a portfolio of commercially attractive biotech products,” stated Dr David Nicholson, executive vice president Global R&D of Organon International.